NuVasive

OverviewSuggest Edit

NuVasive is a medical device company focused on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. Its principal product offering is based on its Maximum Access Surgery, or MAS platform. The MAS platform combines several categories of solutions that collectively minimize soft tissue disruption during spine surgery with maximum visualization and safe, easy reproducibility for the surgeon: a proprietary software-driven nerve avoidance system and intra-operative monitoring support; MaXcess, a unique split-blade retractor system; a wide variety of specialized implants; and several biologic products to aid in the spinal fusion process. MAS significantly reduces surgery time and returns patients to activities of daily living much faster than conventional approaches. 
TypePublic
Founded1997
HQSan Diego, CA, USMap
Websitenuvasive.com
Employee Ratings4More
Overall CultureBMore
View Jobs (2)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)2,800(+8%)
Job Openings2
Revenue (FY, 2019)$1.2 B(+7%)
Share Price (Jan 2021)$56.8
Cybersecurity ratingBMore

Key People/Management at NuVasive

Matt Harbaugh

Matt Harbaugh

Executive Vice President and Chief Financial Officer
Dale Wolf

Dale Wolf

Senior Vice President, Global Operations
Brent Boucher

Brent Boucher

Executive Vice President, Global Commercial
Lucas Vitale

Lucas Vitale

Chief Human Resources Officer
Nathaniel Sisitsky

Nathaniel Sisitsky

Senior Vice President, General Counsel and Corporate Secretary
Massimo Calafiore

Massimo Calafiore

Executive Vice President, Global Business Units
Show more

NuVasive Office Locations

NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations
San Diego, CA, US (HQ)
7475 Lusk Blvd
Aliso Viejo, CA, US
101 Enterprise #100
Columbia, MD, US
10420 Little Patuxent Pkwy #250
Fairborn, OH, US
1 Herald Square
Memphis, TN, US
4670 E Shelby Dr #101
Kew, AU
620 High St
Show all (19)

NuVasive Financials and Metrics

NuVasive Revenue

Embed Graph
View revenue for all periods
NuVasive's revenue was reported to be $1.17 b in FY, 2019
USD

Revenue (Q3, 2020)

295.3m

Gross profit (Q3, 2020)

210.6m

Gross profit margin (Q3, 2020), %

71.3%

Net income (Q3, 2020)

5.9m

Market capitalization (19-Jan-2021)

2.9b

Closing stock price (19-Jan-2021)

56.8

Cash (30-Sept-2020)

774.5m

EV

3.7b
NuVasive's current market capitalization is $2.9 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014Y, 2014Y, 2015FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

478.2m540.5m620.3m685.2m762.4m762.4m811.1m811.1m962.1m1.0b1.1b1.2b

Revenue growth, %

11%6%19%

Cost of goods sold

85.1m112.1m153.4m180.5m182.4m182.4m194.5m194.5m240.1m269.0m311.2m312.4m

Gross profit

393.1m428.4m466.8m504.7m580.1m580.1m616.6m616.6m722.0m760.5m790.6m855.7m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

119.6m120.3m124.5m133.0m132.9m151.7m154.4m148.4m159.5m165.7m169.2m177.5m190.7m189.9m192.4m202.9m200.5m215.1m236.2m239.6m249.9m260.6m247.4m260.5m281.6m271.3m274.8m292.1m290.8m259.9m203.6m295.3m

Cost of goods sold

21.0m21.6m23.5m25.5m26.0m36.9m36.5m37.7m39.1m48.7m43.3m43.3m44.8m47.7m45.7m48.4m49.2m54.2m59.7m59.2m61.6m66.4m65.6m73.8m77.1m74.2m74.5m77.6m77.0m71.9m80.5m84.6m

Gross profit

98.6m98.7m100.9m107.5m106.9m114.8m117.9m110.6m120.4m117.0m125.9m134.2m145.8m142.2m146.7m154.5m151.4m160.9m176.5m180.5m188.3m194.2m181.8m186.7m204.5m197.1m200.3m214.5m213.8m188.0m123.1m210.6m

Gross profit Margin, %

82%82%81%81%80%76%76%75%75%71%74%76%76%75%76%76%75%75%75%75%75%75%73%72%73%73%73%73%74%72%60%71%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

92.6m163.5m123.3m102.8m142.4m192.3m153.6m72.8m117.8m213.0m

Accounts Receivable

76.6m88.4m89.0m104.8m119.0m127.6m199.0m196.5m211.5m

Prepaid Expenses

19.9m8.5m10.9m21.6m8.8m18.8m13.7m16.9m

Inventories

107.6m119.3m126.3m136.9m154.6m168.1m208.2m247.2m273.2m312.4m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

67.5m70.6m134.1m505.1m220.9m270.2m121.2m107.7m78.5m58.9m100.6m110.8m106.5m130.7m88.5m78.6m141.3m270.1m263.1m203.8m134.0m130.9m62.2m73.7m70.1m75.1m93.4m128.4m163.4m512.0m796.8m774.5m

Accounts Receivable

68.2m71.6m76.0m80.5m78.6m85.6m85.7m78.1m90.4m96.3m96.2m106.3m112.6m108.4m111.5m116.8m115.6m126.1m141.9m143.8m172.1m190.2m187.2m188.1m199.9m191.6m194.4m208.0m203.6m186.8m182.1m205.3m

Prepaid Expenses

4.7m5.1m9.2m8.1m7.3m9.1m9.0m10.1m11.3m11.8m10.2m9.0m8.4m7.3m7.8m8.1m9.6m12.9m12.3m9.2m21.1m23.6m23.4m13.6m14.6m14.6m17.3m17.7m15.6m

Inventories

93.1m98.8m114.4m118.0m122.6m122.0m128.6m133.0m129.6m137.4m140.7m147.7m157.4m159.7m163.4m163.7m164.9m200.7m201.9m212.8m223.1m236.8m249.0m258.0m259.8m271.3m288.5m297.1m308.9m324.7m312.2m305.6m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

78.3m(69.8m)3.1m7.0m(17.5m)65.3m35.4m81.3m12.5m65.2m

Depreciation and Amortization

36.7m36.2m51.9m63.1m82.3m83.8m125.4m141.7m149.9m135.6m

Inventories

(18.7m)(17.2m)(11.0m)(21.0m)(21.3m)(26.0m)(22.6m)(35.3m)(38.6m)(54.9m)

Accounts Payable

11.6m(3.4m)2.9m21.8m22.3m7.7m11.9m(5.6m)20.5m(3.3m)
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

7.8m16.4m2.4m7.7m(59.8m)673.0k3.5m5.9m851.0k(5.6m)1.9m(18.3m)(22.4m)(24.2m)31.4m41.4m54.2m(9.3m)26.0m29.5m12.3m24.6m57.7m(27.1m)(15.6m)322.0k9.4m24.3m35.4m5.3m(44.7m)(38.8m)

Depreciation and Amortization

17.1m27.4m7.8m15.9m24.8m12.1m25.3m38.2m14.6m30.3m46.3m15.4m31.0m46.5m20.4m41.4m62.3m26.3m57.3m90.7m34.9m69.6m104.6m37.0m74.1m111.4m39.3m78.1m101.2m35.0m70.1m106.1m

Inventories

(4.3m)(10.0m)(6.7m)(12.1m)(19.9m)(3.5m)(11.0m)14.2m(4.1m)(13.7m)(16.7m)(11.7m)(20.9m)(27.2m)(11.4m)(15.2m)(19.8m)9.4m12.0m(22.4m)(13.6m)(29.0m)(36.2m)(12.1m)(19.6m)(33.5m)(19.3m)(31.9m)(45.6m)(21.1m)(33.0m)(37.5m)

Accounts Payable

4.6m6.3m4.0m(2.3m)504.0k7.8m7.1m4.5m10.4m8.8m10.4m4.5m5.1m16.0m17.4m6.8m8.8m10.0m14.3m5.9m593.0k5.0m(5.9m)1.6m9.0m21.7m(2.5m)9.3m7.4m(5.3m)1.3m10.2m
show all
USDQ2, 2010

Financial Leverage

2.1 x
Show all financial metrics

NuVasive Acquisitions / Subsidiaries

Company NameDateDeal Size
SafePassageDecember 12, 2017
Biotronic NeuroNetworkJune 06, 2016$98 m
Ellipse TechnologiesJanuary 05, 2016$410 m

NuVasive Cybersecurity Score

Cybersecurity ratingPremium dataset

B

83/100

Learn more about our premium products
SecurityScorecard logo

NuVasive Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

Learn more about our premium products
CSRHub logo

NuVasive Online and Social Media Presence

NuVasive's Trends

Embed Graph

NuVasive Company Culture

  • Overall Culture

    B

    75/100

  • CEO Rating

    A+

    83/100

  • Compensation

    D

    54/100

Learn more on Comparably

NuVasive News and Updates

January 11, 2021

Global Spinal Fusion Market Analysis and Forecast Model to 2030, Featuring Key Players Medtronic plc, NuVasive Inc, DePuy Synthes Inc, Globus Medical Inc and More

Dublin, Jan. 11, 2021 (GLOBE NEWSWIRE) -- The "Spinal Fusion (Orthopedic Devices) - Global Market Analysis and Forecast Model (COVID-19 Market Impact)" report has been added to ResearchAndMarkets.com's offering. The model discusses in detail the impact of COVID-19 on Spinal Fusion market for the …
December 16, 2020

Insights on the Minimally Invasive Surgery Global Market to 2027 - Featuring NuVasive, Siemens Healthineers & Stryker Among Others

Dublin, Dec. 16, 2020 (GLOBE NEWSWIRE) -- The "Minimally Invasive Surgery - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. The publisher brings years of research experience to the 7th edition of this report. The 194-page report presents conci…
December 07, 2020

NuVasive to Feature its C360 Portfolio at the Cervical Spine Research Society 48th Annual Meeting

SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a silver level sponsor and feature...
October 27, 2020

NuVasive to Participate as Gold Level Sponsor at SMISS Annual Forum

SAN DIEGO, Oct. 27, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced it will participate as a gold level sponsor at the Society...
October 26, 2020

Cell Therapy Market New Business Experts Ideas By Kolon TissueGene, MEDIPOST, NuVasive, Fibrocell Science, Cells for Cells

Cell therapy (CT) is the process of transplanting human cells to replace or repair damaged tissue or cells. Various methods can be used to carry out cell therapy. For instance, hematopoietic stem cell transplantation, also known as bone marrow transplant, is the most widely used cell therapy. It is …
September 09, 2020

NuVasive Expands Precice Portfolio with First-of-its-Kind Plate for Pediatric Limb Lengthening and Reconstruction Procedures

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, today announced the limited availability of the new Precice® Plate for use...
Show more

NuVasive Blogs

January 07, 2021

NuVasive to Present at the 23rd Annual Needham Virtual Growth Conference

SAN DIEGO , Jan. 7, 2021 /PRNewswire/ --   NuVasive, Inc. (NASDAQ: NUVA), the leader in spine technology innovation, focused on transforming spine surgery with minimally disruptive, procedurally integrated solutions, announced today that management will present at the 23 rd Annual Needham Virtual
January 07, 2021

23rd Annual Needham Virtual Growth Conference

23rd Annual Needham Virtual Growth Conference marco.guevara@… Thu, 01/07/2021 - 14:34 23rd Annual Needham Virtual Growth Conference Display "add to calendar" true Event Type Other Corporate Click here for webcast …
January 06, 2021

NuVasive's X360 Procedural Approach Validated in Clinical Study Published in The Spine Journal Finding Single-Position Spine Surgery Improves Operative Efficiency While Reducing Complications and Length of Hospital Stay

NuVasive's X360 Procedural Approach Validated in Clinical Study Published in The Spine Journal Finding Single-Position Spine Surgery Improves Operative Efficiency While Reducing Complications and Length of Hospital Stay marco.guevara@… Wed, 01/06/2021 - 08:33 NuVasive's X360 Procedural App…
January 04, 2021

39th Annual Virtual J.P. Morgan Healthcare Conference

39th Annual Virtual J.P. Morgan Healthcare Conference marco.guevara@… Mon, 01/04/2021 - 16:18 39th Annual Virtual J.P. Morgan Healthcare Conference Display "add to calendar" true Event Type Other Corporate Click here for web…
January 04, 2021

NuVasive to Participate in 39th Annual Virtual J.P. Morgan Healthcare Conference

NuVasive to Participate in 39th Annual Virtual J.P. Morgan Healthcare Conference Content Import Mon, 01/04/2021 - 16:08 NuVasive to Participate in 39th Annual Virtual J.P. Morgan Healthcare Conference January 04, 2021 This release is a backfill from a News Wi…
December 28, 2020

NuVasive Patient Success Story: Lee

Since its inception in 2010, NuVasive’s the Better Way Back (TBWB) program has been committed to raising public awareness of spine disorders and educating patients, loved ones, clinicians, and healthcare providers about treatment options, including surgery. Changing patient lives and empowering pati…
Show more

 NuVasive Frequently Asked Questions

  • When was NuVasive founded?

    NuVasive was founded in 1997.

  • Who are NuVasive key executives?

    NuVasive's key executives are Matt Harbaugh, Dale Wolf and Brent Boucher.

  • How many employees does NuVasive have?

    NuVasive has 2,800 employees.

  • What is NuVasive revenue?

    Latest NuVasive annual revenue is $1.2 b.

  • What is NuVasive revenue per employee?

    Latest NuVasive revenue per employee is $417.2 k.

  • Who are NuVasive competitors?

    Competitors of NuVasive include Stryker, Integra LifeSciences and Cook Medical.

  • Where is NuVasive headquarters?

    NuVasive headquarters is located at 7475 Lusk Blvd, San Diego.

  • Where are NuVasive offices?

    NuVasive has offices in San Diego, Aliso Viejo, Columbia, Fairborn and in 14 other locations.

  • How many offices does NuVasive have?

    NuVasive has 19 offices.